Zheng‐Yi Zhou

1.7k citations
91 papers · 1.2k indexed · h-index 18
Topics
Lung Cancer Treatments and Mutations (15 papers)Hemophilia Treatment and Research (11 papers)Multiple Myeloma Research and Treatments (10 papers)

In The Last Decade

Zheng‐Yi Zhou

81 papers receiving 1.2k citations

Peers

Zheng‐Yi Zhou
Comparison fields: 5 of 104
  • Hematology 351
  • Oncology 335
  • Pulmonary and Respiratory Medicine 305
  • Molecular Biology 299
  • Cancer Research 219
Replace Carlos Palacio with:
Carlos Palacio Spain
R. Sridhara United States
Takashi Kaneko Japan
Masoud Davanlou United States
Yeşim Eralp Türkiye
Kari G. Chaffee United States
Senthil Rajappa India
Luigi Di Lauro Italy
Chadi Nabhan United States
Ajay Gogia India
Zheng‐Yi Zhou relative to Carlos Palacio Spain Carlos Palacio's profile →
Citations per field
00.5×4.0×
Carlos Palacio · 1×
Citations per year

Countries citing papers authored by Zheng‐Yi Zhou

Since Specialization
Citations

This map shows the geographic impact of Zheng‐Yi Zhou's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Zheng‐Yi Zhou with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Zheng‐Yi Zhou more than expected).

Fields of papers citing papers by Zheng‐Yi Zhou

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Zheng‐Yi Zhou. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Zheng‐Yi Zhou. The network helps show where Zheng‐Yi Zhou may publish in the future.

Co-authorship network of co-authors of Zheng‐Yi Zhou

This figure shows the co-authorship network connecting the top 25 collaborators of Zheng‐Yi Zhou. A scholar is included among the top collaborators of Zheng‐Yi Zhou based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Zheng‐Yi Zhou. Zheng‐Yi Zhou is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
#WorkIndexed citations
1 1
2 0
3 0
4 2
5 1
6 0
7 1
8 20
9 3
10 1
11 0
12 14
13 3
14 4
15 3
16 22
17
Treatment patterns among adults with ADHD receiving long-acting therapy.
1
18 35
19 2
20 19

About Zheng‐Yi Zhou

Zheng‐Yi Zhou is a scholar working on Hematology, General Decision Sciences and Oncology, having authored 91 papers that have together received 1.2k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (15 papers), Hemophilia Treatment and Research (11 papers) and Multiple Myeloma Research and Treatments (10 papers). The work is most often cited by research in Hematology (351 citations), Cancer Research (219 citations) and Oncology (335 citations). Zheng‐Yi Zhou has collaborated with scholars based in United States, China and United Kingdom. Frequent co-authors include Kathleen A. Johnson, Wenxi Tang, Jipan Xie, Annie Guérin, Joel W. Hay, Alex Mutebi, Guohui Yang, Tiemei Li, Deguo Han and James Signorovitch. Their work appears in journals such as Nature Communications, Journal of Clinical Oncology and Blood.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026